浙江圣达生物药业股份有限公司关于2026年度日常关联交易预计的公告

Group 1 - The core point of the announcement is that Zhejiang Shengda Biological Pharmaceutical Co., Ltd. has approved the expected daily related transactions for 2026, which are deemed necessary for normal business operations and will not harm the interests of shareholders, especially minority and non-related shareholders [1][2][3] - The board of directors held a special meeting on February 6, 2026, where independent directors unanimously agreed that the expected related transactions for 2026 are fair and reasonable, aligning with the company's strategic development [2][3] - The board meeting on February 10, 2026, approved the expected daily related transactions, with non-related directors voting in favor, and the proposal did not require submission to the shareholders' meeting [3][4] Group 2 - The expected related transactions for 2026 include purchasing cardboard boxes from Rongsheng Paper Industry for up to 4 million yuan, renting idle houses from Shengbo Trading for 225,000 yuan per year, and engaging in various transactions with other related parties such as Hefei Anke and Changming Pharmaceutical, with expected amounts of 5.1 million yuan and 15.8 million yuan respectively [10][11][12][13] - The pricing policy for these related transactions is based on market principles, ensuring fairness and transparency, and there are no conflicts of interest that would harm the company or its shareholders [14][15] Group 3 - The purpose of these related transactions is to enhance operational efficiency, provide employee accommodations, utilize idle resources, and improve profitability through collaboration with related parties [14][15] - The company has established a management system for foreign exchange hedging to mitigate risks associated with currency fluctuations, with a maximum limit of 150 million yuan for engaging in foreign exchange derivative transactions [22][23][24] - The board has authorized the chairman or general manager to sign relevant agreements for foreign exchange derivative transactions, ensuring compliance with regulatory requirements [29][30]